Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 8/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 3/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349356 | 0.76 | KIF11 (0.50) | PIK3CDMPLKIF11FFAR4 | |
| SCHEMBL29403371 | 0.76 | KIF11 (0.50) | PIK3CDMPLKIF11FFAR4 | |
| SCHEMBL22353104 | 0.75 | AR (0.46) | KIF11CYP1A2 | |
| Hydrochloric Acid SCHEMBL8644024 | 0.74 | KIF11 (0.48) | PIK3CDMPLKIF11FFAR4 | |
| SCHEMBL5020247 | 0.74 | SCN2A (0.46) | NOTUMKIF11 | |
| SCHEMBL22353099 | 0.73 | GAA (0.58) | KIF11PDE3BPDE3ATRPA1 | |
| SCHEMBL2464408 | 0.73 | METAP2 (0.38) | NOTUMMPLKIF11 | |
| SCHEMBL5020244 | 0.72 | SCN2A (0.56) | NOTUM | |
| SCHEMBL13411815 | 0.72 | POLB (0.33) | — | |
| SCHEMBL24427241 | 0.72 | CYP2A6 (0.43) | CDK2FLT3CCNA1PIK3CDMPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200339545-A1 | Compounds And Their Use For Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10752613-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339545-A1 | Compounds And Their Use For Reducing Uric Acid Levels | XDH, OAT, PON1 | CDK2 2701/4885FLT3 1165/4885CCNA1 2844/4885 |
| US-11161835-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | CDK2 2701/4885FLT3 1165/4885CCNA1 2844/4885 |
| US-10752613-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | CDK2 2701/4885FLT3 1165/4885CCNA1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.